secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001682
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dare Bioscience reports FY2024 cash $15.7M, plans Sildenafil Cream 503B launch in Q4 2025
--------------------------------------------------------------------------------

- Cash and equivalents $15.7M at Dec 31, 2024; working capital deficit of $3.2M.
- G&A expenses $9.2M (down 24% YoY); R&D expenses $14.2M (down 34% YoY).
- Plans to make proprietary Sildenafil Cream 3.6% available via 503B compounding in Q4 2025; expects revenue and cash flow from Q4.
- Ovaprene Phase 3 contraceptive study ongoing; half of 125 participants to complete ~6 months by Q2 2025 for interim DSMB review.
- DARE-LARC1 received $3.5M grant in 2024; total $31.8M of up to $49M foundation grant received to date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225001682/0001641172-25-001682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000164117225001682/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer